Role of α₂-Antiplasmin in Fibrin-Specific Clot Lysis with Single-Chain Urokinase-Type Plasminogen Activator in Human Plasma

Summary

The role of plasma α₂-antiplasmin (α₂-AP) in the fibrinspecificity of clot lysis by recombinant single-chain urokinase-type plasminogen activator (rscu-PA) and in the conversion of rscu-PA to its two-chain derivative (rtcu-PA, urokinase) was investigated in an in vitro human plasma clot lysis system. Fifty % lysis in 2 h of a 0.1 ml ¹²⁵l-fibrin labeled human plasma clot immersed in 0.5 ml normal human plasma was obtained with 1.4 ± 0.15 µg/ml rscu-PA (mean ± SD, n = 8). This was associated with degradation of 23 ± 7% of fibrinogen and generation of 0.20 ± 0.09 µg/ml rtcu-PA. In α₂-AP-depleted plasrna 50% clot lysis in 2 h required 2-fold less rscu-PA which was associated with 3-fold more extensive fibrinogen degradation and 2-fold more rtcu-PA generation. Fifty % lysis in? h, of a 0.1 ml α₂-AP-depleted plasma clot, subriersed in 0.5 ml normal plasma, was obtained with 0.80 ± 0.05 µg/ml rscu-PA (n = 3, p <0.001 vs normal clot) and was associated with 17 ± 6% fibrinogen breakdown (p : 0.22 vs normal clot) and 0.08 ± 0.02 µg/ml rtcu-PA generation (p < 0.05 vs normal clot). In α₂-AP-depleted plasma the equipotent rscu-PA concentration was 4-fold lower than in normal plasma and was associated with 3-fold more fibrinogen degradation and a similar extent of rtcu-PA generation

Thus, α₂-AP in plasma contributes significantly to the fibrinspecificity of rscu-PA, primarily via prevention of conversion in plasma of rscu-PA to rtcu-PA. Clot associated α₂-AP increases the resistance of the clot to lysis with rscu-PA, but plays an only minor role in the fibrin-specificity of clot lysis in normal plasma.

• References

• 1 Collen D. Report of the meeting of the subcommittee on fibrinolysis, San Diego, July 13, 1985. Thromb Haemostas 1985; 54: 893
• 2 Hussain SS, Gurewich V, Lipinski B. Purification and partial characteruation of a single-chain high-molecular-weight form of urokinase from human urine. Arch Biochem Biophys 1983; 220: 31-38
• 3 Stump DC, Thienpont M, Collen D. Urokinase-related proteins in human urine. J Biol Chem 1986; 261: 1267-1273
• 4 Wun TC, Schleuning WD, Reich E. Isolation and characteruation of urokinase from human plasma. J Biol Chem 1982; 257: 3276-3243
• 5 Nielsen LS, Hansen JG, Skriver L, Wilson EL, Kaltoft K, kuthen J, Dano K. Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry 1982; 21: 6410-6415
• 6 Sumi H, Maruyama M, Matsuo O, Mihara H, Toki N. Higher fibrinbinding and thrombolytic properties of single polypeptide chain-high molecular weight urokinase. Thromb Haemostas 1982; 47: 297
• 7 Kohno T, Hopper P, Lillquist JS, Suddith RL, Greenlee R, Moir DT. Kidney plasminogen activator: a precursor form of human urokinase with high fibrin affinity. Biotechnology 1984; 2: A844
• 8 Stump DC, Lijnen HR, Collen D. Purification and characteruation of single-chain urokinase-type plasminogen activator from human cell cultures. J Biol Chem 1986; 261: 1274-1278
• 9 Zamarron C, Lijnen HR, Van Hoef B, Collen D. Biological and thrombolytic properties of proenzyme and active forms of human urokinase - I Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology. Thromb Haemostas 1984; 52: 19-23
• 10 Gurewich Y, Pannell R, Louie S, Kelley R, Suddith RL, Greenlee R. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species. J Clin Invest 1984 73. 1731-1739
• 11 Guerrzler WA, Steffens GJ, Oetting S, Buse G, Flohe L. Structural relationship between human high and low molecular mass urokinase. Hoppe Seyler’s Z Physiol Chem 1982; 363: 133-141
• 12 Holmes WE, Pennica D, Blaber M, Rey MW, Guenzler WA, Steffens GJ, Heyneker HL. Cloning and expression of the gene for prourokinase in Escherichia coli. Biotechnology 1985; 3: 923-929
• 13 Wun TC, Ossowski L, Reich E. A proenzyme form of human urokinase. J Biol Chem 1982; 257: 7262-7268
• 14 Ellis V, Scully MR, Kakkar W. Plasminogen activation by singlechain urokinase in functional isolation. A kinetic study. J Biol Chem 1987; 262: 14998-15003
• 15 Lijnen HR, Van Hoef B, Nelles L, Collen D. Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mut agenued plasminogen (Ser⁷⁴⁰ → Ala) and plasmin resistant scu-PA (Lys¹⁵⁸ → Glu). J Biol Chem 1990; 265: 5232-5236
• 16 Kasai S, Arimura H, Nishida M, Suyama T. Proteolytic cleavage of single-chain pro-urokinase induces conformational change which follows activation of the zymogen and reduction of its high affinity for fibrin. J Biol Chem 1985; 260: 12377-12381
• 17 Petersen LC, Lund LR, Nielsen LS, Dano K, Skriver L. One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J Biol Chem 1988; 263: 11189-11195
• 18 Lijnen HR, Zamarron C, Blaber M, Winkler ME, Collen D. Activation of plasminogen by pro-urokinase. I Mechanism. J Biol Chem 1986; 261: 1253-1258
• 19 Van de Werf I, Nobuhara M, Collen D. Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (ptourokinase) in patients with acute myocardial infarction. Ann Intern Med 1986; 104: 345-348
• 20 PRIMI Trial Study Group. Randomised double-blind trial of recombinant pro-urokinase in acute myocardial infarction. Lancet 1989 . 863-868
• 21 Lijnen HR, Van Hoef B, De Cock R, Collen D. The mechanism of plasminogen activatibn and fibrin dissolution by single-chain urokinase-type plasminogen activator in a plasma milieu in vitro. Blood 1989; 73: 1864-1872
• 22 Declerck PJ, Lijnen ff, Verstreken M, Moreau FI, Collen D. A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma. Blood 1990 75. 1794-1800
• 23 Wiman B. Affinity-chromatographic purification of human α₂-antiplasmin. Biochem J 1980; 191: 229-242
• 24 Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem 1978; 84: 573-578
• 25 Fraker PJ, Speck Jr JC. Protein and cell membrane iodinations with a sparingly soluble chloroamide 1, 3, 4, 6-tetrachloro-3a, 6a-diphenylglycoluril. Biochem Biophys Res Commun 1978; 80: 848-857
• 26 Holvoet R, de Boer A, Verstreken M, Collen D. An enzyme-linked immunosorbent assay (ELISA) for the measurement of plasmin α₂- antiplasmin complex in human plasma. Application to the detection of in vivo activation of the fibrinolytic system. Thromb Haemostas 1986 56. 124-127
• 27 Lijnen HR, Uytterhoeven M, Collen D. Inhibition of trypsin-like serine proteinases by tripeptide arginyl and lysil chloromethylketones. Thromb Res 1984; 34: 431-437
• 28 Reed GL, Matsueda GR, Haber E. Synergistic fibrinolysis: combined effects of plasminogen activators and an antibody that inhibits α₂-antiplasmin. Proc Natl Acad Sci USA 1990; 87: 1114-1118